Marken Launches Exclusive Shipping System for Specimen Logistics
Marken announced the launch of its new BioSystem shipping system, designed specifically for biological samples, to further enhance its global biological logistics services. Marken has leveraged its extensive global experience in clinical specimens transport and has designed a system with technology for prolonged temperature control while also standardizing box size for optimum freight costs and dry ice use. Marken will deploy these new systems, together wits already proven logistics management style, across their global network of 24 locations which currently support over 49,000 investigators in more than 150 countries.
The Marken BioSystem is designed to assure product integrity throughout the temperature controlled chain in three standard sizes: 5Kgs, 9Kgs and 15Kgs volumetric weight. Each size is rated to keep biological products frozen for 72 hours or more. The systems have been engineered to be environmentally friendly, validated to conform to ISTA 7E enhanced protocol and are regionally IATA PI620 approved for the transport of biological specimens.
Additionally, the new boxes are expected to reduce greenhouse emissions by up to 40% with a decreased carbon footprint from the reduction of styrene, cardboard and use of less dry ice to achieve greater performance at the same cost as conventional solutions.
The BioSystem series is a first of its kind. It will be globally available. It will allow for universal standardization in all clinical protocols and will support all regions with one consistent application. Clinical researchers will soon have a single global solution to transport specimens using consistent packaging and services from the most remote sites in Europe, Asia, Middle East and the Americas.
The new BioSystem packaging is the latest enhancement to Marken’s global clinical trials support services which includes GMP storage conditions, 24/7/365 proactive temperature management, active monitoring throughout the cold chain, packaging collection and recycling. Marken also offers onsite training and regulatory consulting for all countries.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
